Cargando…

Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR(®)) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation

PURPOSE: We conducted exposure-response modeling and simulations to compare the predicted efficacy of extended-release oxcarbazepine (OXC-XR), an oral once-daily (qd) antiepileptic drug, with that of immediate-release (IR) OXC twice-daily (bid) when the agents are used as monotherapy or adjunctive t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faison, Shamia, Gomeni, Roberto, Mendes, Shannon, O’Neal, Welton, Schwabe, Stefan, Nasser, Azmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520464/ https://www.ncbi.nlm.nih.gov/pubmed/33061671 http://dx.doi.org/10.2147/CPAA.S256972

Ejemplares similares

Long‐term efficacy and safety of adjunctive extended‐release oxcarbazepine (Oxtellar XR(®)) in adults with partial‐onset seizures
por: Chung, S. S., et al.
Publicado: (2015)

Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial
por: French, JA, et al.
Publicado: (2014)

Update on once-daily zonisamide monotherapy in partial seizures
por: Afra, Pegah, et al.
Publicado: (2014)

Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults
por: Mula, Marco
Publicado: (2013)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2020)

The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2022)

Oxcarbazepine monotherapy in children with benign epilepsy with centrotemporal spikes improves quality of life
por: Liu, Wan-Ting, et al.
Publicado: (2020)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

Oxcarbazepine and Hyponatremia
por: Čiauškaitė, Julija, et al.
Publicado: (2022)

Tacrolimus monotherapy in a patient with lupus flare using once-daily administration protocol
por: Tanaka, Hiroshi, et al.
Publicado: (2011)

Effects of levetiracetam and oxcarbazepine monotherapy on intellectual and cognitive development in children with benign epilepsy with centrotemporal spikes
por: Suo, Gui-hai, et al.
Publicado: (2021)

Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
por: Yi, Jia-Qin, et al.
Publicado: (2023)

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
por: Findling, Robert L., et al.
Publicado: (2021)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Benefits of once-daily therapies in the treatment of hypertension
por: Flack, John M, et al.
Publicado: (2011)

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Oxcarbazepine as monotherapy of acute mania in insufficiently controlled type-1 diabetes mellitus: a case-report
por: Oulis, Panagiotis, et al.
Publicado: (2007)

Effectiveness and Safety of Oxcarbazepine vs. Levetiracetam as Monotherapy for Infantile Focal Epilepsy: A Longitudinal Cohort Study
por: Zhao, Binyang, et al.
Publicado: (2022)

Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal epilepsy: A systematic review and meta‐analysis
por: Kharel, Sanjeev, et al.
Publicado: (2022)

Corrigendum: Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
por: Yi, Jia-Qin, et al.
Publicado: (2023)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products
por: Gomeni, Roberto, et al.
Publicado: (2022)

Dosimetric evaluation of GAFCHROMIC® XR type T and XR type R films
por: Dini, Sharifeh A., et al.
Publicado: (2005)

Uncontrolled headache induced by oxcarbazepine
por: Piovesan, Elcio Juliato, et al.
Publicado: (2007)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

Ultraviolet exposure of Gafchromic XR‐RV3 and XR‐SP2 films
por: Katsuda, Toshizo, et al.
Publicado: (2015)

Once-daily, oral levofloxacin monotherapy for low-risk neutropenic fever in cancer patients: a pilot study in China
por: He, Lixian, et al.
Publicado: (2015)

A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury
por: La Fountaine, Michael F., et al.
Publicado: (2019)

Once-daily USL255 as adjunctive treatment of partial-onset seizures: Randomized phase III study
por: Chung, Steve S, et al.
Publicado: (2014)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Oxcarbazepine May Be Useful in Sydenham Chorea
por: Işıkay, Sedat, et al.
Publicado: (2021)

Cisco IOS XR fundamentals
por: Tahir, Mobeen
Publicado: (2009)

Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
por: Sunkaraneni, Soujanya, et al.
Publicado: (2017)

Comparison of Lamotrigine and Oxcarbazepine Monotherapy Among Chinese Adult Patients With Newly-Diagnosed Focal-Onset Epilepsy: A Prospective Observational Study
por: Chen, Yuncan, et al.
Publicado: (2022)

Functional analysis of a novel de novo SCN2A variant in a patient with seizures refractory to oxcarbazepine
por: Hu, Xiaoyue, et al.
Publicado: (2023)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

Cutaneous adverse drug reactions induced by Oxcarbazepine
por: Hsiao, Yi-Hsin, et al.
Publicado: (2014)

606 Case Report: Hypogammaglobulinemia Induced by Oxcarbazepine
por: Marinovic, Maria Angelica, et al.
Publicado: (2012)

Desensitization to Oxcarbazepine: Long-Term Efficacy and Tolerability
por: Lee, Jiwon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_om88qi8ovpbvtop2a6sbvfoais